In the latest look at clinical trial transparency, a new analysis found that only 26% of drug makers made results publicly available for all studies used to win approval for their medicines during a recent two-year period.
The total rose to 67% when examining trials that were conducted in patients for indications approved by the Food and Drug Administration. But just 58% of the trials met legal requirements for registering and disclosing results for drugs that were approved in 2016 and 2017. And 11% of the drugs did not have any trials for which results were legally required to be reported at the time of their approval.
Overall, larger companies were more transparent than smaller ones. And there was a statistically significant difference between biologics and drugs — 85% versus 47% — when it came to public availability of all trial results. Notably, nearly all of the biologics — 19 of 22 — were developed by large companies. Company size was determined by market capitalization.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
